Veeva Systems

Overview

Veeva Systems is the dominant cloud software and data vendor serving the global life sciences industry. Founded in 2007 by Peter Gassner (a former Salesforce VP) and Matt Wallach, Veeva was purpose-built on a vertical SaaS thesis: that regulated, science-driven industries like pharma would pay a premium for software that understood their compliance obligations, data models, and workflows. Veeva went public in 2013 at a $4 billion valuation; it now operates at approximately $3.2 billion in annual revenue (FY2026, ending January 31, 2026) and serves more than 1,500 customers, including 15 of the top 20 global biopharma companies.

Veeva’s CRM commands an estimated 80% global market share in life sciences field force software. Its Vault platform underlies content management, regulatory submissions, clinical operations, and quality management at the majority of large pharma companies. Its data products — Compass, Crossix, and OpenData — are increasingly positioned as alternatives to the IQVIA data stack that the industry has relied on for decades.

In December 2022, Veeva announced it would not renew its Salesforce platform partnership, electing to migrate its entire CRM business onto its proprietary Vault platform. That migration — the largest technology transition in pharma commercial software history — is currently underway, with peak activity expected 2026-2029. Veeva is incorporated as a Public Benefit Corporation.

Services & Capabilities

Commercial Cloud

Vault CRM (formerly Veeva CRM): The flagship product, now migrated off Salesforce to Veeva’s proprietary Vault architecture. As of March 2026, over 125 customers are live on Vault CRM globally, including multiple top-20 biopharma companies. Core capabilities include call planning, closed-loop marketing, sample management, approved email, compliant remote detailing, and territory management. Pricing is estimated at approximately $120-$150 per user per month for large deployments. The legacy Salesforce-based CRM entered maintenance mode in late 2023, with end-of-support accelerated to December 31, 2029.

Veeva AI Agents: Launched December 3, 2025, embedded within Vault Platform. Includes Pre-call Agent (generates engagement plans from CRM, Compass, and Crossix data), Voice Agent (hands-free data capture), and Free Text Agent (compliance flagging). Safety/Quality agents scheduled for April 2026; Clinical/Regulatory/Medical August 2026; Clinical Data December 2026. Built on Anthropic and Amazon Bedrock LLMs with usage-based pricing.

Veeva Network (MDM): Master data management for HCP and HCO data governance. Following the August 2025 IQVIA-Veeva settlement, IQVIA’s OneKey data can now flow directly into Veeva Network.

Veeva Nitro: Cloud data warehouse optimized for life sciences commercial analytics. Integrates data from Vault CRM, Compass, and third-party sources including IQVIA data post-partnership.

Veeva PromoMats (Vault): Industry-standard content management for promotional materials — digital asset management, MLR review workflows, claims management, and multi-channel content distribution.

Data Cloud

Veeva Compass: Modern alternative to IQVIA’s Xponent and DDD prescriber data products. Covers 300M+ U.S. patients, 4M+ HCPs, 110B+ prescription and medical records with 8+ years of history. Includes Compass Patient (APLD), Compass Prescriber, Compass National, Compass Pathway (specialty channel), and Compass Data Connector. Key differentiator is unlimited-access licensing (flat subscription, unrestricted internal use).

Veeva Crossix: Acquired 2019 for ~$430M. HIPAA-compliant patient analytics and media measurement platform connecting health data from 300M+ patients with media exposure data from 150+ publishers. Measures DTC and HCP digital media impact on prescribing behavior. Uses SafeMine federated processing for HIPAA compliance. As of December 2025, Crossix data feeds directly into Vault CRM AI Agents’ Pre-call recommendations.

Veeva OpenData: Global HCP/HCO reference data competing with IQVIA’s OneKey. US: 12M HCPs, 2M HCOs. Europe: 5M HCPs, 2M HCOs across 52 countries. Additional coverage in Latin America (14 countries), Asia Pacific (11 countries), Middle East/Africa (22 countries), and China (5M HCPs, 1M HCOs). Flat subscription pricing per country.

Development Cloud (R&D and Quality)

Built entirely on the Vault platform with application suites for clinical, regulatory, quality, and safety:

• Vault Clinical Suite: EDC, CTMS, eTMF, RTSM, Study Startup, eConsent, Site Connect. Competes with Medidata Rave EDC and Oracle Clinical One.
• Vault RIM: Regulatory submissions dossier management, global registration tracking, labeling, and publishing.
• Vault Safety (Pharmacovigilance): Adverse event intake, case processing, E2B submissions, signal detection. Q4 FY2026 marked sixth top-20 biopharma win in Safety.
• Vault QualityOne / LIMS: Document management, training, quality management, lab information systems. First top-20 biopharma go-live at two manufacturing sites in 2026.

Competitive Position

vs. Salesforce + IQVIA Life Sciences Cloud

The most significant structural development in pharma CRM since 2017. In April 2024, IQVIA licensed its OCE CRM to Salesforce for co-development of the Salesforce Life Sciences Cloud, launched September 2025. Veeva’s structural advantages: single-platform architecture, purpose-built GxP compliance, deep switching costs from validated workflows embedded in SOPs, and growing proprietary data assets. Vulnerabilities: premium pricing (~2x generic alternatives), Salesforce’s AI velocity, and migration execution risk during the 2026-2029 mass migration window.

vs. IQVIA OCE

IQVIA OCE has ~400 customers in 130 countries but less than 10% pharma CRM market share. IQVIA’s competitive weapon is data (OneKey, Xponent, patient-level RWD), not software. The August 2025 settlement ended eight years of litigation and established mutual data access agreements, representing a detente that benefits both parties’ customers.

vs. Medidata (Dassault Systemes) in Clinical

Medidata serves 2,100+ life sciences customers; its Rave platform underpins ~90% of recent U.S. oncology NDA submissions. Veeva Vault EDC is gaining share among sponsors standardized on the Vault ecosystem but lacks Medidata’s longitudinal trial data repository. The eClinical solutions market is projected to reach $25.2B by 2030.

Recent Developments

• Vault CRM GA (April 2024): 125+ customers live by March 2026. End-of-support for legacy CRM accelerated to December 31, 2029.
• Veeva-Salesforce Separation (September 2025): Non-compete formally expired.
• IQVIA Settlement and Partnership (August 2025): Comprehensive data interoperability agreements after eight years of litigation; no damages exchanged.
• AI Agents Launch (December 2025): Production release for Vault CRM and PromoMats.
• Ostro Acquisition (March 2026): AI-driven brand engagement platform for pharma websites, ~$100M in cash.
• Salesforce Life Sciences Cloud Launch (September 2025): Most credible long-term competitive threat to Veeva’s commercial dominance.

Financial Profile

Metric	FY2024	FY2025	FY2026	FY2027 Guidance
Total Revenue	$2,358M	$2,747M	$3,195M	$3,585-3,600M
YoY Growth	—	+16.5%	+16.3%	~12-13%
Subscription Revenue	$1,902M	$2,285M	$2,684M	~$3,040M
Non-GAAP Op. Margin	~38.6%	~42.0%	~44.8%	~44.3%
Non-GAAP Diluted EPS	$5.22	$6.60	$8.10	~$8.85

Development Cloud (R&D + Quality) is now larger than Commercial Cloud in subscription revenue (FY2027 guidance: ~$1,660M R&D/Quality vs. ~$1,380M Commercial). Veeva carries over $3 billion in net cash with no meaningful debt. Net revenue retention for multi-application Vault customers exceeds 120%. TAM exceeds $20B against ~$3.2B TTM revenue.

Sources

Primary source: raw/research/01_veeva_systems.md. Financial data from Veeva Systems investor relations and SEC filings. Product and market data from Veeva.com, IntuitionLabs, Bloomberg Law, BioXconomy, MarketsandMarkets, and industry analyst publications.